Base de dados : LILACS
Pesquisa : D12.776.543.750.705.852.760.949.249 [Categoria DeCS]
Referências encontradas : 46 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 46 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1104226
Autor: Pavlov, Sergey; Babenko, Nataliia; Kumetchko, Marina; Litvinova, Olga; Semko, Natalia; Pavlova, Olga.
Título: Intercellular mediators in bone remodeling regulation in the experimental renal pathology / Mediadores intercelulares de la regulación de la remodelación ósea en un modelo experimental de patología renal
Fonte: Actual. osteol;15(3):180-191, Sept-Dic. 2019. ilus.
Idioma: en.
Resumo: Bone metabolism disorders are characterized by an imbalance of bone resorption and formation in the bone remodeling process. Glucocorticoids that are used to treat kidney diseases exacerbate these disorders. P-selectin and galectin-3 are molecules involved in the sclerotic process in kidney, whereas bone resorption is regulated by the interaction between the nuclear factor activator kappa b receptor (RANK), its ligand (RANKL) and the RANKL decoy receptor osteoprotegerin (OPG). The aim of this study was to investigate the cellular and molecular mechanisms of disruption of bone remodeling regulation processes, reflected by intercellular mediators (RANKL, OPG, P-selectin and galectin-3) in chronic kidney disease experimental model treated with glucocorticoids. Rats were divided into four groups of 10 animals each. The first group, the control group, included intact animals. The second group consisted of rats with impaired bone remodeling resulting from chronic kidney disease (experimental group (CKD). The third group was a group of animals with impaired bone remodeling due to exposure to glucocorticoids (experimental group (GCs)). The fourth group consisted of rats with impaired bone remodeling in chronic kidney disease, followed by exposure to glucocorticoids (experimental group (CKD + GCs)). The effects of CKD and glucocorticoid were evaluated biochemically, histologically and by measuring bone density. An enzymelinked immunoassay was used to measure intercellular mediator levels in the serum. The bone density in the experimental groups was reduced compared to the control group. RANKL levels in animals of three experimental groups were higher than in intact animals. Serum levels of OPG were higher in CKD and GCs groups than in intact animals. At the same time, in the animals' blood serum of the CKD + GCs group, the levels of OPG were lower, than those in animals from the control group. The levels of galectin-3 in the serum of the experimental groups GCs and CKD + GCs were lower than in intact animals. The serum levels of galectin-3 in animals of the CKD group were higher than those in animals from the control group. The levels of P-selectin were lower in the serum of the GCs group than in intact animals. At the same time, the levels of P-selectin were higher in the CKD and CKD + GCs groups, than those in animals from the control group. In conclusion, the study of the complex system of bone remodeling regulation, which includes many factors and their interactions, may lead to the development of new methods for treating patients with chronic kidney disease in order to prevent osteoporosis in the future. (AU)

Las enfermedades metabólicas óseas se caracterizan por un desequilibrio en el proceso de remodelación ósea en los que participan mediadores tales como receptor del activador del factor nuclear- kappa- b (RANK), su ligando (RANKL) y la osteoprotegerina (OPG). Los glucocorticoides, recuentemente empleados en el tratamiento de la enfermedad renal crónica, exacerban este desequilibrio. En la enfermedad esclerótica renal, las moléculas de adhesión celular P-selectina and galectina-3 tienen un rol fundamental. El objetivo de esta trabajo fue estudiar las alteraciones en los mediadores de la remodelación ósea (RANKL, OPG, P-selectina and galectina-3) en un modelo de enfermedad renal crónica con tratamiento glucocorticoideo. Ratas Wistar hembras fueron divididos en 4 grupos: control (C); enfermedad renal crónica con afección de la remodelación ósea (ERC); animales con afección de la remodelación ósea expuestos a glucocorticoides (GC); enfermedad renal crónica con afección de la remodelación ósea tratados con glucocorticoides (ERC+GC). Los efectos de la ERC y los GC fueron evaluados bioquímicamente, histológicamente y por medición de la densidad ósea. RANKL, OPG, Pselectina and galectina-3 se cuantificaron en muestras de sangre venosa empleando enzimoinmuno análisis. En los 3 grupos experimentales la densidad ósea se evidenció reducida y los niveles séricos de RANKL elevados respecto al grupo control. Los niveles de OPG en los grupos ERC y GC fueron superiores mientras que en el grupo ERC+GC menores respecto a los animales controles. Galectina 3 plasmática en GC y ERC+GC se encontró reducida y aumentada en los animales ERC, en comparación con los animales controles. La concentración sérica de P-selectina sérica fue mayor en los grupos ERC y ERC+GC, y menor en los animales GC respecto a los niveles plasmáticos de los animales intactos. El avance del conocimiento sobre la regulación de la remodelación ósea a través de la interacción de mediadores sistémicos, en un futuro, puede conducir al desarrollo de nuevas estrategias terapéuticas para la prevención de la osteoporosis en pacientes con enfermedad renal crónica. (AU)
Descritores: Distúrbio Mineral e Ósseo na Doença Renal Crônica/induzido quimicamente
Remodelação Óssea/efeitos dos fármacos
Nefropatias/fisiopatologia
-Osteoporose/prevenção & controle
Doenças Ósseas Metabólicas/diagnóstico
Dexametasona/administração & dosagem
Densidade Óssea/efeitos dos fármacos
Clorofórmio/uso terapêutico
Ratos Wistar
Selectina-P/efeitos dos fármacos
Selectina-P/sangue
Galectina 3/efeitos dos fármacos
Galectina 3/sangue
Ligante RANK/efeitos dos fármacos
Ligante RANK/sangue
Osteoprotegerina/efeitos dos fármacos
Osteoprotegerina/sangue
Glucocorticoides/efeitos adversos
Glicerol/administração & dosagem
Nefropatias/tratamento farmacológico
Limites: Animais
Ratos
Tipo de Publ: Ensaio Clínico Controlado Aleatório Veterinário
Responsável: AR2.1 - Biblioteca Central


  2 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1019970
Autor: Borges, Cristine D Almeida; Ricoldi, Milla Sprone; Messora, Michel Reis; Palioto, Daniela Bazan; Souza, Sérgio Luís Scombatti de; Novaes Júnior, Arthur Belém; Taba Jr, Mario.
Título: Clinical attachment loss and molecular profile of inflamed sites before treatment
Fonte: J. appl. oral sci;27:e20180671, 2019. tab, graf.
Idioma: en.
Projeto: State of São Paulo Foundation (FAPESP); . Coordenação de Nível Superior - Brasil (CAPES).
Resumo: Abstract Objective: To monitor early periodontal disease progression and to investigate clinical and molecular profile of inflamed sites by means of crevicular fluid and gingival biopsy analysis. Methodology: Eighty-one samples of twenty-seven periodontitis subjects and periodontally healthy individuals were collected for the study. Measurements of clinical parameters were recorded at day −15, baseline and 2 months after basic periodontal treatment aiming at monitoring early variations ofthe clinical attachment level. Saliva, crevicular fluid and gingival biopsies were harvested from clinically inflamed and non-inflamed sites from periodontal patients and from control sites of healthy patients for the assessment of IL-10, MMP-8, VEGF, RANKL, OPG and TGF-β1 protein and gene expression levels. Results: Baseline IL-10 protein levels from inflamed sites were higher in comparison to both non-inflamed and control sites (p<0.05). Higher expression of mRNA for IL-10, RANK-L, OPG, e TGF-β1 were also observed in inflamed sites at day −15 prior treatment (p<0.05). After the periodontal treatment and the resolution of inflammation, seventeen percent of evaluated sites still showed clinically detectable attachment loss without significant differences in the molecular profile. Conclusions: Clinical attachment loss is a negative event that may occur even after successful basic periodontal therapy, but it is small and limited to a small percentage of sites. Elevated inflammation markers of inflamed sites from disease patients reduced to the mean levels of those observed in healthy subjects after successful basic periodontal therapy. Significantly elevated both gene and protein levels of IL-10 in inflamed sites prior treatment confirms its modulatory role in the disease status.
Descritores: Perda da Inserção Periodontal/patologia
-Periodontite/terapia
Saliva/química
Fatores de Tempo
Biópsia
Biomarcadores/análise
Estudos de Casos e Controles
Citocinas/análise
Líquido do Sulco Gengival/química
Estatísticas não Paramétricas
Metaloproteinase 8 da Matriz/análise
Fator A de Crescimento do Endotélio Vascular/análise
Osteoprotegerina/análise
Reação em Cadeia da Polimerase em Tempo Real
Gengiva/patologia
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR28.1 - Serviço de Biblioteca e Documentação Professor Doutor Antônio Gabriel Atta


  3 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Silva, Léa Assed Bezerra da
Texto completo
Id: biblio-1040231
Autor: Andrucioli, Marcela Cristina Damião; Matsumoto, Mírian Aiko Nakane; Fukada, Sandra Yasuyo; Saraiva, Maria Conceição Pereira; Bergamo, Ana Zilda Nazar; Romano, Fábio Lourenço; Silva, Raquel Assed Bezerra da; Silva, Lea Assed Bezerra da; Nelson-Filho, Paulo.
Título: Quantification of pro-inflammatory cytokines and osteoclastogenesis markers in successful and failed orthodontic mini-implants
Fonte: J. appl. oral sci;27:e20180476, 2019. tab, graf.
Idioma: en.
Projeto: São Paulo Research Foundation - Process number.
Resumo: Abstract Objectives: Miniscrew has been frequently used, considering that anchorage control is a critical point in orthodontic treatment, and its failure, the main adverse problem. Using two groups of stable (successful) and unstable (failed) mini-implants, this in vivo study aimed to quantify proinflammatory cytokines IL-1 α, IL-6, IL-17, and TNF-α and osteoclastogenesis marker RANK, RANKL, and OPG in gingival tissue, using the real-time polymerase chain reaction technique. Methodology: Thirteen patients of both sexes (11-49 years old) under orthodontic treatment were selected, obtaining 11 successful and 7 failed mini-implants. The mini-implants were placed and removed by the same surgeon, in both jaws. The mean time of permanence in the mouth was 29.4 months for successful and 7.6 months for failed mini-implants. At removal time, peri-mini-implant gingival tissue samples were collected and processed for quantification of the proinflammatory cytokines and osteoclastogenesis markers. Nonparametric Wilcoxon rank-sum test considering the clusters and Kruskal-Wallis test were used for statistical analysis (α=0.05). Results: No significant difference (p>0.05) was observed between the groups for either quantification of cytokines or osteoclastogenesis markers, except for IL-6 (p<0.05). Conclusions: It may be concluded that the expression of IL-1α, IL-17, TNF-α, RANK, RANKL, and OPG in peri-implant gingival tissue were not determinant for mini-implant stability loss, but the higher IL-6 expression could be associated with mini-implant failure.
Descritores: Osteogênese/fisiologia
Implantes Dentários/efeitos adversos
Citocinas/análise
Procedimentos de Ancoragem Ortodôntica/efeitos adversos
Peri-Implantite/patologia
Gengivite/patologia
-Valores de Referência
Fatores de Tempo
Biomarcadores/análise
Perda do Osso Alveolar
Resultado do Tratamento
Estatísticas não Paramétricas
Osteoprotegerina/análise
Reação em Cadeia da Polimerase em Tempo Real
Limites: Humanos
Masculino
Feminino
Criança
Adolescente
Adulto
Pessoa de Meia-Idade
Responsável: BR28.1 - Serviço de Biblioteca e Documentação Professor Doutor Antônio Gabriel Atta


  4 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1090768
Autor: Ma, Zongmin; Li, Shuxian; Sun, Yuchen.
Título: Effect of enhanced masticatory force on OPG, RANKL and MGF in alveolar bone of ovariectomized rats
Fonte: J. appl. oral sci;28:e20190409, 2020. graf.
Idioma: en.
Projeto: National Natural Science Foundation of China.
Resumo: Abstract Menopause induces oral bone loss, leading to various oral diseases. Mastication importantly affects bone metabolism in the jawbone. Objective: To analyze the effect of enhanced masticatory force on osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), and mechano-growth factor (MGF) in alveolar bone of ovariectomized rats and to study the mechanics mechanism of the alveolar bone of ovariectomized rats response to enhanced masticatory force. Methodology: Thirty Sprague Dawley rats were randomly divided into three groups: sham-operation group (fat around the removed ovary + normal hard diet), model group (ovariectomy + normal hard diet), and experimental group (ovariectomy + high hard diet). It was a 2-month experiment. Enzyme-linked immunosorbent assay (ELISA) detected serum estradiol (E2), osteocalcin (BGP) and alkaline phosphatase (ALP) in rats. Bone histomorphometric indices in the third molar region of maxilla were detected by micro-CT; protein expressions of OPG, RANKL, and MGF in the third molar region of maxilla was detected by Western blot; and gene expression of OPG, RANKL, and MGF in the third molar region of maxilla was detected by Quantitative Real-Time PCR. Results: Comparing with model group, serum E2 in experimental group increased but not significantly, serum BGP and serum ALP in experimental group decreased but not significantly, OPG in experimental group in alveolar bone increased significantly, RANKL in experimental group in alveolar bone decreased significantly, RANKL/OPG ratio in experimental group decreased significantly, MGF in experimental group in alveolar bone increased significantly, bone volume to total volume fraction increased significantly in experimental group, trabecular thickness increased significantly in experimental group, and trabecular separation decreased significantly in experimental group. Conclusion: Enhanced masticatory force affected the expression of OPG, RANKL, and MGF in alveolar bone of ovariectomized rats, improved the quality of jaw bone of ovariectomized rats, and delayed oral bone loss by ovariectomy.
Descritores: Força de Mordida
Fator de Crescimento Insulin-Like I/análise
Ovariectomia
Ligante RANK/análise
Osteoprotegerina/análise
Processo Alveolar/fisiopatologia
-Osteocalcina/sangue
Western Blotting
Reação em Cadeia da Polimerase
Ratos Sprague-Dawley
Fosfatase Alcalina/sangue
Estradiol/sangue
Microtomografia por Raio-X
ELISPOT
Limites: Animais
Feminino
Responsável: BR28.1 - Serviço de Biblioteca e Documentação Professor Doutor Antônio Gabriel Atta


  5 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1119580
Autor: Tenório, Jefferson da Rocha.
Título: Avaliação dos níveis séricos e salivares de RANKL, OPG, IL-1?, IL-6 e TNF-? e sua relação com o índice da cortical mandibular em pacientes com cirrose hepática / Evaluation of serum and salivary levels of RANKL, OPG, IL-1?, IL-6 and TNF-? and their association with mandibular cortical index in patients with liver cirrhosis.
Fonte: São Paulo; s.n; 20200000. 81 p.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Odontologia para obtenção do grau de Doutor.
Resumo: Pacientes com cirrose hepática podem desenvolver osteoporose como complicação relacionada ao déficit funcional hepático. O objetivo desse estudo é o de avaliar a presença de proteínas relacionadas ao metabolismo ósseo (RANKL, OPG, IL-1?, IL-6 e TNF-?) na saliva e no sangue de pacientes cirróticos e compará-los com o índice da cortical mandibular (ICM), relacionado à densidade mineral óssea, em radiografias panorâmicas. Trinta e oito pacientes cirróticos foram submetidos à anamnese, exame físico e tiveram amostras de sangue e de saliva não estimulada coletadas. Desses, 22 apresentavam radiografias panorâmicas que foram avaliadas segundo o ICM. As proteínas foram avaliadas através da tecnologia LuminexTM xMAP. Foram considerados estatisticamente significativos valores de p <=0.05. A maioria dos pacientes era do sexo masculino (68,4%), com idade média de 50,61 anos, média de MELD de 18 pontos no momento da consulta e média de 21,34 meses na fila de espera para o transplante. A análise das radiografias panorâmicas permitiu constatar que a maior parte da amostra apresentava alguma modificação na cortical mandibular sugestiva de alterações osteoporóticas (72,7%). O perfil de expressão das proteínas foi bastante variável no sangue e na saliva. Correlação estatisticamente significativa foi observada entre a expressão salivar de RANKL e OPG em pacientes com ICM alterado. Não foi observada relação estatisticamente significante entre o perfil das proteínas e a etiologia da cirrose, tempo na fila de transplante hepático, idade e sexo dos pacientes. As proteínas RANKL, OPG, IL-1?, IL-6 e TNF-? se comportam de maneira diferente na saliva e no sangue. Valores elevados de RANKL e OPG em saliva estão relacionados com ICM sugestivo de osteoporose em pacientes cirróticos, e propõe-se que esse aumento ocorra devido ao microambiente inflamatório local.
Descritores: Osteoporose
Radiografia Panorâmica
Ligante RANK
Osteoprotegerina
Inflamação
-Cirrose Hepática
Responsável: BR97.1 - Serviço de Documentação Odontológica


  6 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886206
Autor: Zhang, Chun; Liao, Qi; Ming, Jiang-Hua; Hu, Ge-Liang; Chen, Qing; Liu, Shi-Qing; Li, Ya-Ming.
Título: The effects of chitosan oligosaccharides on OPG and RANKL expression in a rat osteoarthritis model
Fonte: Acta cir. bras;32(6):418-428, June 2017. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To investigate the effect of chitosan oligosaccharides (COS) against osteoarthritis (OA) and preliminarily discuss the osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL) and RANK expression in a rat OA model. Methods: Thirty-six 6-week-old Male SD rats were randomly divided into three groups: sham-operated group(CON), OA-induction group(OA), COS intervention group(n=12/group). At 4 weeks after the operation, COS (50 ul) intervention weekily for consecutive 5 weeks. The OA and CON groups received an injection of 50 ul physiological saline. At death, 11 weeks following surgery, cartilage was harvested and total RNA and protein were extracted. Both the morphological changes of the cartilage were observed and harvested the total RNA and protein. Meanwhile, the expression of OPG, RANKL and RANK in cartilage were determined. Results: The expression of OPG and RANKL were both enhanced in the cartilage of the OA model. Compared with the OA group, COS treatment improved the cartilage damage (both extent and grade). Furthermore, the COS group showed highly OPG and lower RANKL. Simultaneously, COS treatment upregulated the ratio of OPG/RANKL and downregulated the RANKL/RANK. Conclusion: Chitosan oligosaccharides may be used as a unique biological agent to prevent and treat osteoarthritis, and this effect is associated with modulation of the expression of osteoprotegerin and receptor activator of NF-κB ligand.
Descritores: Oligossacarídeos/farmacologia
Osteoartrite/metabolismo
Cartilagem Articular/efeitos dos fármacos
Quitosana/farmacologia
Ligante RANK/metabolismo
Osteoprotegerina/metabolismo
-Cartilagem Articular/metabolismo
Regulação da Expressão Gênica
Ratos Sprague-Dawley
Modelos Animais de Doenças
Osteoprotegerina/efeitos dos fármacos
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  7 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-973330
Autor: Sánchez, Ariel; Raggio, Juan Carlos; Valtorta, Emiliano.
Título: Cascada de fracturas vertebrales en paciente osteoporótica al año de suspender Denosumab / Cascade of vertebral fractures in osteoporotic patient one year after Denosumab
Fonte: Rev. med. Rosario;84(1):22-25, ene.-abr. 2018. ilus.
Idioma: es.
Resumo: Una paciente con osteoporosis había sido tratada por 4 años con ibandronato oral, luego por 1 año con ranelato de estroncio, y finalmente por 4 años con denosumab. En vista de la buena respuesta densitométrica este fármaco fue suspendido a fines de 2015. A los 14 meses la enferma tuvo lumbalgia aguda y se detectó hundimiento del platillo superior de L1, a lo que siguieron en rápida sucesión iguales lesiones en L2 y L3, y acuñamiento de D11 y D12. Se descartaron causas de osteoporosis secundaria. El plan terapéutico incluye corsé ortopédico, analgésicos, y teriparatida. En los dos últimos años se han publicado varios casos de este síndrome.

A patient with osteoporosis had been treated for 4 years with oral ibandronate, then for 1 year with strontium ranelate, and finally for 4 years with denosumab. In view of the good densitometric response to the latter, the drug was discontinued in December 2015. Fourteen months later the patient had acute low back pain; crushing of the upper plate of L1 was detected, followed by similar lesions in L2 and L3, and wedging of D11 and D12. Causes of secondary osteoporosis were ruled out. The therapeutic strategy includes a corset, analgesics, and teriparatide. In the last two years several cases of this syndrome have been reported.
Descritores: Anticorpos Monoclonais
Anticorpos Monoclonais/efeitos dos fármacos
Osteoporose Pós-Menopausa/prevenção & controle
Fraturas da Coluna Vertebral/diagnóstico
Fraturas da Coluna Vertebral/prevenção & controle
-Osteoprotegerina
Osteoprotegerina/efeitos dos fármacos
Resultado do Tratamento
Limites: Humanos
Feminino
Idoso de 80 Anos ou mais
Tipo de Publ: Relatos de Casos
Responsável: AR16.1 - Biblioteca


  8 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Almeida, Maria das Gracas
Texto completo
Texto completo
Id: biblio-889416
Autor: Loureiro, Melina Bezerra; Ururahy, Marcela Abbott Galvão; Souza, Karla Simone Costa de; Oliveira, Yonara Monique da Costa; Silva, Heglayne Pereira Vital da; Bortolin, Raul Hernandes; Bezerra, João Felipe; Hirata, Rosario Dominguez Crespo; Maciel-Neto, José Jorge; Arrais, Ricardo Fernando; Almeida, Maria das Graças; Hirata, Mario Hiroyuki; Rezende, Adriana Augusto de.
Título: Relationship between glycemic control and OPG gene polymorphisms with lower bone mineral density in patients with type 1 Diabetes mellitus
Fonte: Braz. J. Pharm. Sci. (Online);53(4):e00060, 2017. tab.
Idioma: en.
Projeto: CNPq.
Resumo: ABSTRACT The aim of the present study was to investigate the bone mineral density (BMD) of patients with type 1 Diabetes mellitus (T1DM). We also assessed the association between osteoprotegerin (OPG) genetic polymorphisms and BMD. Genotyping was performed for 1181G>C and 163A>G OPG polymorphisms by allelic discrimination in 119 patients with T1DM and 161 normoglycemic (NG) individuals, aged 6 to 20 years old. Glycemic control, serum parameters of bone metabolism and BMD were evaluated. T1DM patients showed low BMD, poor glycemic control and decreased total calcium values when compared to controls (p < 0.05). For all the polymorphisms studied, the genotype and allele frequencies in patients with T1DM were not significantly different from the controls. In patients with T1DM, carriers of OPG 1181CC showed higher concentrations of ionized calcium compared to patients with GG+GC genotypes. These results suggest that low BMD is associated with poor glycemic control in T1DM. Despite the lack of a detected association between OPG polymorphisms and BMD in these patients, the increased ionized calcium in those carrying OPG 1181CC suggests a possible increase in osteoclastogenesis, a conclusion that may be supported by the lower BMD observed in these subjects.
Descritores: Polimorfismo Genético
Densidade Óssea/genética
Índice Glicêmico/imunologia
Diabetes Mellitus Tipo 1/classificação
-Osteogênese Imperfeita/prevenção & controle
Osteoprotegerina
Técnicas de Genotipagem/métodos
Limites: Humanos
Masculino
Feminino
Criança
Adolescente
Adulto
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  9 / 46 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-888712
Autor: Gibertoni, Fabrício; Sommer, Meire Ellen Ligia; Esquisatto, Marcelo Augusto Marretto; Amaral, Maria Esméria Corezola do; Oliveira, Camila Andrea de; Andrade, Thiago Antônio Moretti de; Mendonça, Fernanda Aparecida Sampaio; Santamaria-Jr, Milton; Felonato, Maíra.
Título: Evolution of Periodontal Disease: Immune Response and RANK/RANKL/OPG System
Fonte: Braz. dent. j;28(6):679-687, Nov.-Dec. 2017. tab, graf.
Idioma: en.
Projeto: FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo).
Resumo: Abstract The aim of this study was to evaluate markers of bone loss and immune response present in evolution of periodontal disease. One hundred and two Wistar rats were divided into three animals groups: PD0, without ligation and PD15 days and PD60 days, submitted to ligation placement with a sterile 3-0 silk cord in the cervical region of the upper first molar on both sides. Samples were obtained from the gingival tissue for histomorphometric analysis, immunohistochemical analysis of RANK, RANKL, OPG, characterization of the inflammatory infiltrate, quantification of nitric oxide, MCP-1, RANTES, IP10 chemokines, and expression of the TGF-b1, VEG, and bFGF. The number of inflammatory cells in gingival tissue was higher in PD60 samples. The collagen content and the area occupied by birefringent collagen fibers were lower for PD60. Differential leukocyte counting showed that there was a significantly higher polymorphonuclear influx in group PD15, while PD60 showed a greater number of lymphocytes. PD60 showed higher RANTES, IP-10, MCP-1 gene transcripts, as well as a higher nitric oxide concentration. Clinical evaluation revealed that the PD60 group presented an increase in furcal area. In conclusion, in this animal model the increase of RANK/RANKL and HGF markers is related to a specific immune response, and probably contributed to the evolution of periodontal disease. Investigating the effect of these biomarkers can help in targeted therapy for bone resorption, since blocking these can inhibit bone loss.

Resumo Este estudo avaliou marcadores de perda óssea e da resposta imune presentes na evolução da doença periodontal. Cento e dois ratos Wistar foram divididos em três grupos de animais: PD0, sem ligadura e PD15 dias e PD60 dias, submetidos a colocação de ligadura com um fio de seda estéril 3-0 na região cervical do primeiro molar superior em ambos os lados. Foram obtidas amostras de tecido gengival para análise histomorfométrica, análises imunohistoquímicas de RANK, RANKL, OPG, caracterização do infiltrado inflamatório, quantificação de óxido nítrico, expressão de quimiocinas MCP-1, RANTES, IP10 e do TGF-b1, VEGF e bFGF . O número de células inflamatórias no tecido gengival foi maior nas amostras PD60. O teor de colágeno na área ocupada pelas fibras de colágeno birrefringentes foram menores para PD60. A contagem diferencial de leucócitos mostrou que houve um influxo polimorfonuclear significativamente maior no grupo PD15, enquanto que PD60 mostrou número maior de linfócitos. PD60 apresentou transcritos de genes RANTES, IP-10, MCP-1 mais elevados, bem como uma maior concentração de óxido nítrico. A avaliação clínica revelou que o grupo PD60 apresentou aumento da área óssea exposta na região da furca. Em conclusão, neste modelo animal o aumento dos marcadores RANK/RANKL e HGF está relacionado a uma resposta imunológica específica e provavelmente contribuiu para a evolução da doença periodontal. Investigar o efeito destes biomarcadores pode ajudar na terapia dirigida para a reabsorção óssea, uma vez que bloquear estes pode inibir a perda óssea.
Descritores: Doenças Periodontais/imunologia
Ligante RANK/metabolismo
Receptor Ativador de Fator Nuclear kappa-B/metabolismo
Osteoprotegerina/metabolismo
-Doenças Periodontais/metabolismo
Imuno-Histoquímica
Western Blotting
Ratos Wistar
Quimiocinas/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Inflamação/metabolismo
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  10 / 46 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Volpon, José B
Texto completo
Id: biblio-840064
Autor: Spirlandeli, Adriano L; Dick-de-Paula, Ingrid; Zamarioli, Ariane; Jorgetti, Vanda; Ramalho, Leandra NZ; Nogueira-Barbosa, Marcello H; Volpon, Jose B; Jordão, Alceu A; Cunha, Fernando Q; Fukada, Sandra Y; de Paula, Francisco JA.
Título: Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment
Fonte: Clinics;72(4):231-237, Apr. 2017. tab, graf.
Idioma: en.
Projeto: CNPq; . NAP-DIN; . CNPq.
Resumo: OBJECTIVES: The present study was designed to evaluate the bone phenotypes and mechanisms involved in bone disorders associated with hepatic osteodystrophy. Hepatocellular disease was induced by carbon tetrachloride (CCl4). In addition, the effects of disodium pamidronate on bone tissue were evaluated. METHODS: The study included 4 groups of 15 mice: a) C = mice subjected to vehicle injections; b) C+P = mice subjected to vehicle and pamidronate injections; c) CCl4+V = mice subjected to CCl4 and vehicle injections; and d) CCl4+P = mice subjected to CCl4 and pamidronate injections. CCl4 or vehicle was administered for 8 weeks, while pamidronate or vehicle was injected at the end of the fourth week. Bone histomorphometry and biomechanical analysis were performed in tibiae, while femora were used for micro-computed tomography and gene expression. RESULTS: CCl4 mice exhibited decreased bone volume/trabecular volume and trabecular numbers, as well as increased trabecular separation, as determined by bone histomorphometry and micro-computed tomography, but these changes were not detected in the group treated with pamidronate. CCl4 mice showed increased numbers of osteoclasts and resorption surface. High serum levels of receptor activator of nuclear factor-κB ligand and the increased expression of tartrate-resistant acid phosphatase in the bones of CCl4 mice supported the enhancement of bone resorption in these mice. CONCLUSION: Taken together, these results suggest that bone resorption is the main mechanism of bone loss in chronic hepatocellular disease in mice.
Descritores: Doenças Ósseas Metabólicas/etiologia
Doenças Ósseas Metabólicas/tratamento farmacológico
Remodelação Óssea/efeitos dos fármacos
Difosfonatos/farmacologia
Conservadores da Densidade Óssea/farmacologia
Hepatopatias/complicações
-Fósforo/administração & dosagem
Osso e Ossos/efeitos dos fármacos
Osso e Ossos/metabolismo
Osso e Ossos/diagnóstico por imagem
Doenças Ósseas Metabólicas/metabolismo
Reabsorção Óssea/metabolismo
Tetracloreto de Carbono
Modelos Animais de Doenças
Subunidade alfa 1 de Fator de Ligação ao Core/genética
Ligante RANK/genética
Osteoprotegerina/genética
Microtomografia por Raio-X
Fosfatase Ácida Resistente a Tartarato/genética
Cirrose Hepática/induzido quimicamente
Cirrose Hepática/metabolismo
Hepatopatias/metabolismo
Camundongos Endogâmicos C57BL
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde